Vertex posts strong 2nd-qtr 2026 results

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) reported consolidated financial results for the second quarter ended June 30, 2026, and updated its full year 2026 revenue guidance after markets closed on Monday.

Total revenue increased 12% to $3.33 billion compared to the second quarter of 2025, (beating consensus by ~$110 million), primarily driven by the continued performance of cystic fibrosis (CF) therapies and growth from diversification into additional disease areas. In the US, total revenue increased 11% to $2.06 billion due to continued strong CF patient demand, including from new initiations of Alyftrek (deutivacaftor/tezacaftor/vanzacaftor); higher realized net prices in CF versus the prior year; and contributions from Casgevy (exagamglogene autotemcel) and Journavx (suzetrigine). Outside the USA, total revenue increased 14% to $1.28 billion due to strong CF performance across multiple geographies, including Alyftrek uptake; increased Casgevy  infusions; and a favorable impact from foreign exchange.